Pricing for childhood vaccines are referencing the current Center for Disease Control and Preventions (CDC) Federal Contract for Vaccine…

Merck Sharp & Dohme Corp has been awarded a Texas contract (HHSTX-6-0000407384) effective June 23, 2026, for the provision of childhood vaccines and related pharmaceutical products. The contract pricing references the Centers for Disease Control and Prevention (CDC) Federal Contract for Vaccine and Biologicals (CDC Federal Contract Number: 75D30126D20729). The primary deliverable encompasses pediatric immunization products, with specific focus on diphtheria, tetanus, and whole-cell pertussis vaccine formulations, classified under UNSPSC code 51201632 and NIGP code 26980 (Serums, Toxoids, and Vaccines).

The contract encompasses a broader pharmaceutical portfolio beyond core vaccine offerings, as evidenced by the multiple UNSPSC classifications including immunomodulating drugs based on tyrosine kinase inhibitors (UNSPSC 51202000), hyaluronan compounds (UNSPSC 51202002), and additional therapeutic agents such as Tolvaptan and Thymalfasin. Specific contract value, cumulative value, and period of performance details were not provided in the source documentation. As the prime contractor, Merck Sharp & Dohme Corp will supply these products to the State of Texas, with pricing aligned to established CDC federal contract benchmarks to ensure cost effectiveness and standardization across immunization programs.